Recorded Pharmacist Educational Series: Gene & Cell Therapy Educational Series: Part 5 – Genetically Engineered Cell-based Therapy
ACPE Activity Number:0204-0000-25-088-H01-P/T Release Date: June 25, 2025 Expiration Date: June 25, 2027 Activity Type: Knowledge-based CE Credits: 0.5 contact hour Activity Fee: Member – Free / Non-Member – Not Available
Activity Overview
Gene and cell therapies are quickly integrating into pharmacy practice and present unique challenges not encountered with traditional medications in the clinical pharmacy setting. Health-system pharmacies must take an active role in onboarding these therapies including evaluating biosafety precautions along the medication use pathway, assisting with the development of infrastructure to administer and monitor these therapies, and identifying the practical and financial implications of these therapies within the health-system.
This activity will cover the background of cellular-based gene therapies from basic cell biology to genetic targets currently used in treatment. Experts will review the mechanisms for modifying cellular genetic material and the common viral vector platforms used in ex-vivo cellular therapy production. An overview of the steps and processes for cellular therapy preparation, manufacturing, handling and administration will be provided. Additionally, this presentation will discuss novel cellular therapy agents currently approved for use and the highly anticipated cellular therapies currently under investigation.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This activity was planned to meet the educational needs of all who work in pharmacy settings where cellular therapies are currently or soon to handled.
After participating in this CPE activity, participants should be able to:
Recognize risks, challenges, and patient safety implications associated with the administration of in vivo/viral-based therapies in clinical and research settings.
Identify opportunities to improve management of supportive care therapies used for toxicity prevention.
Identifycollaborative strategies with other institutional stakeholders and committees to educate on and safely integrate these novel therapies in the medication use process.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.
